C.R. Bard, Inc. (NYSE:BCR) VP Betty D. Larson sold 5,906 shares of C.R. Bard stock in a transaction on Friday, October 20th. The shares were sold at an average price of $330.16, for a total value of $1,949,924.96. Following the completion of the sale, the vice president now directly owns 10,753 shares of the company’s stock, valued at approximately $3,550,210.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of C.R. Bard, Inc. (NYSE:BCR) traded up 0.0743% on Tuesday, hitting $328.3838. The company’s stock had a trading volume of 173,302 shares. The stock has a market capitalization of $23.86 billion, a P/E ratio of 43.1120 and a beta of 0.59. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $330.31. The stock’s 50 day moving average price is $321.61 and its 200 day moving average price is $311.84.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.54 earnings per share. On average, analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio is presently 13.67%.

TRADEMARK VIOLATION NOTICE: “C.R. Bard, Inc. (BCR) VP Sells $1,949,924.96 in Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/c-r-bard-inc-bcr-vp-sells-1949924-96-in-stock.html.

A number of large investors have recently modified their holdings of BCR. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in C.R. Bard by 70.4% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares during the period. Parallel Advisors LLC boosted its holdings in C.R. Bard by 283.8% during the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares during the period. Captrust Financial Advisors bought a new stake in C.R. Bard during the second quarter valued at about $192,000. Choate Investment Advisors bought a new stake in C.R. Bard during the second quarter valued at about $201,000. Finally, Stock Yards Bank & Trust Co. bought a new stake in C.R. Bard during the second quarter valued at about $207,000. Hedge funds and other institutional investors own 79.51% of the company’s stock.

A number of brokerages have recently commented on BCR. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. BMO Capital Markets reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. Finally, Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $292.00.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.